Core Thesis - Yelp Inc. is viewed as a compelling investment opportunity due to its deeply discounted trading multiples and the full pricing in of near-term concerns [2][6] Financial Metrics - As of December 1st, Yelp's share price was $28.62, with a trailing P/E of 12.91 and trading at 4x EBITDA, 13x trailing earnings, and 1.4x sales [1][2] - The company has rising EBITDA margins and declining EV/EBITDA ratios, indicating undervaluation compared to peers [4] User Engagement and Brand Strength - Yelp's user base remains engaged, particularly among younger demographics, and the platform enjoys strong brand recognition and trust [3] - The integration into Apple's ecosystem presents strategic optionality, including the potential for acquisition by Apple, which could enhance the platform's reach [3] Shareholder Value and Financial Strategy - Share repurchases have significantly reduced the outstanding share count, although this has not yet been reflected in stock performance [5] - Yelp ranks in the top decile of the Magic Formula, showcasing strong ROIC and EV/EBITDA metrics relative to the broader market [5] Strategic Opportunities - The fragmented ownership and founder-led structure create an environment conducive to activist intervention or strategic transactions [6] - A potential sale to Apple at a premium could unlock substantial value, positioning Yelp's data set as a core asset for AI-driven monetization [6] Overall Investment Profile - Yelp is characterized by a rare combination of undervalued tangible and intangible assets, resilient revenue streams, and strategic optionality, offering a highly asymmetric risk/reward profile for investors [6]

Core Insights - TeraWulf Inc. (NASDAQ:WULF) is identified as one of the best short squeeze stocks to consider for investment, with Citizens reaffirming a Market Outperform rating and a price target of $22 following the third-quarter 2025 earnings report [1] Financial Performance - TeraWulf reported a larger-than-expected loss in Q3 2025, with earnings per share at -$1.13 compared to the anticipated -$0.05, despite a 6% quarter-over-quarter growth in GAAP revenues to $50.6 million [2] - The company's profitability was negatively affected by a 22% decline in self-mined Bitcoins from the previous quarter [2] - TeraWulf plans to enhance its high-performance computing (HPC) capacity by 250–500 megawatts annually [2] Company Evolution - Citizens noted that TeraWulf has transitioned from a "highly-speculative operation" to a company with a clear path to rapidly utilizing the capacity of its two initial sites, supported by new anchor tenant clients demonstrating reliability [3] - TeraWulf specializes in developing, owning, and operating industrial-scale data center infrastructure in the US, specifically designed for Bitcoin mining and HPC hosting [3]

Core Insights - ConocoPhillips (NYSE:COP) is highlighted as one of the top energy stocks to buy, with Wolfe Research reaffirming its Outperform rating and raising the price target to $131 from $130 following an 8% dividend increase [1][2] Financial Performance - The company is projected to achieve significant free cash flow growth, with an estimated $1 billion gain expected between 2026-2028, followed by a $4 billion increase in 2029 [2] - ConocoPhillips anticipates generating an additional $7 billion in free cash flow by 2029 once the Willow project becomes operational [3] Strategic Moves - The completion of the Anadarko acquisition and $0.5 billion in noncore asset dispositions have allowed ConocoPhillips to exceed its $3 billion asset sales target for 2025 [2] - Wolfe Research suggests that ConocoPhillips should be compared to larger energy companies like CNQ and CVX due to its clear free cash flow trajectory, rather than smaller shale-focused exploration and production companies [3] Company Overview - ConocoPhillips is a global energy company based in Texas, involved in the discovery, production, transportation, and trading of crude oil, bitumen, natural gas, liquefied natural gas, and natural gas liquids [4]

Core Insights - Merus N.V. (NASDAQ:MRUS) is highlighted as one of the best biotech stocks to buy, with Barclays initiating coverage and setting a price target of $112 and an Overweight rating [1] - The approval of zenocutuzumab for rare malignancies has validated Merus's platform commercially [1] Group 1: Clinical Developments - Merus's Phase 3 clinical asset, petosemtamab, is undergoing two potentially registration-enabling Phase 3 trials for frontline and previously treated metastatic head and neck cancers [2] - The clinical derisking of petosemtamab in head and neck malignancies, along with potential value creation in colorectal cancer through year-end 2026, presents a significant opportunity for share gain [2] Group 2: Company Overview - Merus N.V. is a biotechnology company focused on developing antibody-based cancer treatments, with key initiatives including Zenocutuzumab and Petosemtamab (MCLA-158) [3]

Group 1 - The article emphasizes a long-term value investing approach, focusing on classical value ratios such as low P/B, P/FCF, and Owner Earnings discounting [1] - It advocates for self-indexing using the Dow Jones Industrial Average combined with Joel Greenblatt's Magic Formula for tax efficiency [1] - The author has a background in private credit and commercial real estate mezzanine financing, with experience working with top developers [1] Group 2 - The article mentions a beneficial long position in shares of major tech companies including NVDA, MSFT, AMZN, GOOGL, and GOOG [2] - It clarifies that the opinions expressed are personal and not influenced by compensation from any mentioned companies [2]

Group 1 - The article discusses the process of identifying stocks for investment by running a simple screening method to find potential candidates for deeper analysis [1] - The author has extensive experience in various investment vehicles including commodities, stocks, options, and futures contracts, leading to a successful trading career [1] Group 2 - There is a disclosure regarding a beneficial long position in the shares of IESC, indicating a personal investment interest [2] - The article emphasizes that past performance does not guarantee future results, highlighting the inherent uncertainties in investment [3]